| Company Name | Exchange | Ticker | Last Price | Day 1 (% Change) | Day 2 (% Change) | 52 WEEK HIGH | 52 WEEK LOW | Last Volume | M.Cap MM ($) |
| Geron Corp | NASDAQ | GERN | 3.15 | 11% | 21% | 7.79 | 1.07 | 47,599,250 | 494.4 |
| TG Therapeutics Inc | NASDAQ | TGTX | 8.82 | 10% | 21% | 8.89 | 2.97 | 1,648,196 | 331.8 |
Geron Corp (NASDAQ: GERN), a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, for blood cancer, gained more than 34% during its past two trading sessions gaining more than 11% in each of the two consecutive days. During its last trading session, the stock jumped 21% closing at $3.15 with significant trading volumes of 47 million shares. During its past 5-trading sessions, GERN surged 53% with 5-day average volume of 14 million shares compared to 1-month daily average volume of 4 million shares.
TG Therapeutics Inc (NASDAQ: TGTX), a clinical-stage biopharmaceutical company focused on development of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, gained more than 33% during its past two trading sessions gaining more than 10% in each of the two consecutive days. During its last trading session, the stock jumped 21% closing at $8.82 with significant trading volumes of 1.6 million shares. During its past 5-trading sessions, TGTX surged 37% with 5-day average volume of 548,005 shares compared to 1-month daily average volume of 302,668 shares.
